What is ProSolus?
ProSolus Pharmaceuticals is a specialized pharmaceutical entity focused on the research, development, and global manufacturing of transdermal and topical patch technologies. The company's diverse product pipeline addresses critical therapeutic areas including pain management, cardiovascular conditions, and neurological disorders. Operating from a state-of-the-art facility in Miami, Florida, ProSolus is dedicated to providing bespoke solutions for its clientele, collaborating with suppliers to advance drug delivery systems and ensure a sophisticated user experience from formulation through to final packaging.
How much funding has ProSolus raised?
ProSolus has raised a total of $637K across 2 funding rounds:
Debt
$350K
Debt
$287K
Debt (2020): $350K with participation from PPP
Debt (2021): $287K led by PPP
What's next for ProSolus?
The enterprise-level funding context surrounding ProSolus Pharmaceuticals suggests a company poised for significant scaling and market expansion. The recent strategic investment indicates confidence from financial backers in the company's innovative approach to transdermal and topical drug delivery. Future endeavors will likely involve broadening the therapeutic applications of their patch technology, enhancing manufacturing capabilities, and potentially pursuing further strategic partnerships to solidify their market position and extend their global reach. Continued investment in research and development will be crucial for maintaining a competitive edge in the dynamic pharmaceutical landscape.
See full ProSolus company page
